DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

American Heart Association; World Heart Federation;
International Atherosclerosis Society; and International
Association for the Study of Obesity. Circulation, 2009,
120:1640–1645.
Alqahtani SA, Sanchez W. Statins are safe for the treatment of
hypercholesterolemia in patients with chronic liver disease.
Gastroenterology, 2008, 135:702–704.
Alsheikh-Ali AA, Karas RH. Adverse events with concomitant
amiodarone and statin therapy. Prev Cardiol, 2005, 8:95–97.
Altmann SW, Davis HR Jr, Zhu L-J, et al. Niemann-Pick C1 like
1 protein is critical for intestinal cholesterol absorption.
Science, 2004, 303:1201–1204.
Amarenco P, Labreuche J. Lipid management in the prevention
of stroke: Review and updated meta-analysis of statins for
stroke prevention. Lancet Neurol, 2009, 8:453–463.
American Diabetes Association. Dyslipidemia management in
adults with diabetes. Diabetes Care, 2004, 27(suppl 1):
S68–S71.
American Heart Association (AHA). Heart Disease and Stroke
Statistics—2004 Update. Dallas, TX, AHA, 2003.
Attie AD. ABCA1: At the nexus of cholesterol, HDL and atherosclerosis.
Trends Biochem Sci, 2007, 32:172–179.
Aung PP, Maxwell H, Jepson RG, et al. Lipid-lowering for
peripheral arterial disease of the lower limb. Cochrane
Database Syst Rev, 2007, 4:CD000123.
Baigent C, Landry M. Study of Heart and Renal Protection
(SHARP). Kidney Int, 2003, 63(suppl 84):S207–S210.
Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety
of ezetimibe co-administered with simvastatin compared with
atorvastatin in adults with hypercholesterolemia. Am J
Cardiol, 2004, 93:1487–1494.
Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe
coadministered with atorvastatin in 628 patients with primary
hypercholesterolemia: A prospective, randomized,
double-blind trial. Circulation, 2003, 107:2409–2415.
Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low
levels of LDL cholesterol, and cardiovascular events. N Engl
J Med, 2007, 357:1301–1310.
Bellosta S, Paoletti R, Corsini A. Safety of statins. Focus on clinical
pharmacokinetics and drug interactions. Circulation,
2004, 109:III-50–III-57.
Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have
a clinically significant pharmacokinetic interaction with fenofibrate
in humans. J Clin Pharmacol, 2004, 44:1054–1062.
Bersot TP, Pépin GM, Mahley RW. Risk determination of dyslipidemia
in populations characterized by low levels of highdensity
lipoprotein cholesterol. Am Heart J, 2003, 146:
1052–1060.
Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, et al.
Apolipoprotein A-II is inversely associated with risk of future
coronary artery disease. Circulation, 2007, 116:2029–2035.
Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical
Evaluation of Lovastatin (EXCEL) Study results. I. Efficacy in
modifying plasma lipoproteins and adverse event profile in
8245 patients with moderate hypercholesterolemia. Arch
Intern Med, 1991, 151:43–49.
Brown BG, Cheung MC, Lee AC, et al. Antioxidant vitamins
and lipid therapy. End of a long romance? Arterioscler Thromb
Vasc Biol, 2002, 22:1535–1546.
Brown RJ, Rader DJ. Lipases as modulators of atherosclerosis in
murine models. Curr Drug Targets, 2007, 8:1307–1319.
Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management
in patients with cardiometabolic risk. Consensus
statement from the American Diabetes Association and the
American College of Cardiology Foundation. Diabetes Care,
2008, 31:811–822.
Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus
moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med, 2004, 350:1495–1504.
Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of
cardiovascular outcomes trials comparing intensive versus
moderate statin therapy. J Am Coll Cardiol, 2006, 48:438–445.
Castelli WP. Making practical sense of clinical trial data in
decreasing cardiovascular risk. Am J Cardiol, 2001,
88(suppl):16F–20F.
Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated
liver enzymes are not at higher risk for statin hepatotoxicity.
Gastroenterology, 2004, 126:1287–1292.
Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration
and coronary heart disease in population with low cholesterol
concentrations. Br Med J, 1991, 303:276–282.
Cheung BMY, Lauder IJ, Lau C-P, Kumana CR. Meta-analysis
of large randomized controlled trials to evaluate the impact of
statins on cardiovascular outcomes. Br J Clin Pharmacol,
2004, 57:640–651.
Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy
and safety of cholesterol-lowering treatment: Prospective
meta-analysis of data from 90 056 participants in 14 randomised
trials of statins. Lancet, 2005, 366:1267–1278.
Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy
of cholesterol-lowering therapy in 18 686 people with diabetes
in 14 randomised trials of statins: A meta-analysis. Lancet,
2008, 371:117–125.
Christian AH, Mills T, Simpson SL, Mosca L. Quality of cardiovascular
disease preventive care and physician/practice characteristics.
J Gen Intern Med, 2006, 21:231–237.
Christians U, Jacobsen W, Floren LC. Metabolism and drug
interactions of 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors in transplant patients: Are the statins
mechanistically similar? Pharmacol Ther, 1998, 80:1–34.
Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B
and cardiovascular disease risk: Position statement from the
AACC Lipoproteins and Vascular Diseases Division Working
Group on Best Practices. Clin Chem, 2009, 55:407–419.
Corsini A. The safety of HMG-CoA reductase inhibitors in special
populations at high cardiovascular risk. Cardiovasc Drugs
Ther, 2003, 17:265–285.
Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic
and pharmacokinetic properties of statins.
Pharmacol Ther, 1999, 84:413–428.
Crouse JR III, Frolich J, Ose L, et al. Effects of high doses of
simvastatin and atorvastatin on high-density lipoprotein cholesterol
and apolipoprotein A-I. Am J Cardiol, 1999, 83:
1476–1477.
Crouse JR, Kastelein J, Isaacsohn J, et al. A large, 36 week study
of the HDL-C raising effects and safety of simvastatin versus
atorvastatin [abstract]. Atherosclerosis, 2000, 151:8–9.
D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P, for the
C. H. D. Risk Prediction Group. Validation of the
Framingham coronary heart disease prediction scores:
Results of a multiple ethnic groups investigation. JAMA,
2001, 286:180–187.
905
CHAPTER 31
DRUG THERAPY FOR HYPERCHOLESTEROLEMIA AND DYSLIPIDEMIA